Search results for " Lung disease"

showing 10 items of 102 documents

<p>Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting&lt…

2019

Background Patients with chronic obstructive pulmonary disease (COPD) show signs of reduced physical activity from the early stages of the disease, impacting morbidity and mortality. Data suggest treatment with tiotropium, a long-acting muscarinic antagonist, and olodaterol, a long-acting s2-agonist (LABA), as monotherapies and in combination, increases exercise capacity. This study assessed the effects of fixed-dose tiotropium/olodaterol (delivered via Respimat®) on physical function in Global Initiative for Chronic Obstructive Lung Disease A-D patients requiring long-acting dual bronchodilation treatment in a real-world setting. Methods This open-label, single arm, noninterventional study…

medicine.medical_specialtyCOPDRespimatbusiness.industryOlodaterolGeneral Medicinemedicine.diseaseConfidence intervalObstructive lung disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePatient satisfaction030228 respiratory systemchemistryInternal medicinemedicineClinical endpoint030212 general & internal medicineAdverse effectbusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

2013

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Usual interstitial pneumonia and nonspecific interstitial pneumonia seem to be the most frequent patterns in RA patients with ILD, although the proportion of patients with usual interstitial pneumonia is higher than among patients with other systemic rheumatic autoimmune diseases. RA patients with ILD most frequently present with chronic symptoms of cough and dyspnea when climbing stairs or walking uphill. A physical examination may reveal inhalatory crackles and a pulmonary function test demonstrates restrictive physiology, often with re…

medicine.medical_specialtyImmunologyArthritisLung biopsyGastroenterologyPulmonary function testingArthritis RheumatoidAntibodies Monoclonal Murine-DerivedPatient Education as TopicUsual interstitial pneumoniaInternal medicinemedicineHumansImmunology and AllergyAntibodies BlockingPneumonitisLeflunomideClinical Trials as TopicTumor Necrosis Factor-alphabusiness.industryInterstitial lung diseaseIsoxazolesmedicine.diseaserespiratory tract diseasesMethotrexateAntirheumatic AgentsRheumatoid arthritisImmunologyLung Diseases InterstitialRituximabbusinessLeflunomidemedicine.drugExpert Review of Clinical Immunology
researchProduct

Iatrogenic pulmonary lesions.

2018

Treatment of patients often includes the administration of medications and sometimes radiation. While the intent is to treat an underlying condition, in some cases, adverse effects occur due to these agents. Most of these adverse effects are mild, however, some can be severe and life-threatening. Furthermore, while these effects are often reversible upon cessation of exposure, especially if the inciting agent is recognized and withdrawn early, others might be permanent or even progressing. Most common histopathologic findings in drug-induced interstitial lung disease include nonspecific interstitial pneumonia (cellular and/or fibrotic), organizing pneumonia with or without bronchiolitis, eo…

medicine.medical_specialtyPathologyDrug-Related Side Effects and Adverse ReactionsPolymersIatrogenic DiseaseAmiodaroneAntineoplastic Agents030204 cardiovascular system & hematologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineEarly Medical InterventionmedicineEosinophilic pneumoniaHumansImmunologic FactorsIntensive care medicineDiffuse alveolar damageAdverse effectLungLungRadiotherapybusiness.industryInterstitial lung diseasePulmonary edemamedicine.diseasemedicine.anatomical_structureEquipment and SuppliesNitrofurantoin030220 oncology & carcinogenesisPulmonary hemorrhagebusinessLung Diseases InterstitialAnti-Arrhythmia AgentsHydrophobic and Hydrophilic InteractionsHypersensitivity pneumonitisSeminars in diagnostic pathology
researchProduct

Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis

2016

Background: Interstitial lung disease (ILD) complicates the course of systemic sclerosis (SSc) up to two-third of the cases, representing the main cause of death in these patients. Assessment of lung involvement by HRCT and close monitoring of lung function are mandatory. At present no serologic biomarkers are validated for the assessment for lung damage in SSc. The current study was designed to test the hypothesis that the levels of surfactant are altered in SSc compared to healthy controls. To this aim serum levels of SP-A (Surfactant Protein A) and SP-D (Surfactant Protein-D) in serum were assessed. Methods: We enrolled 12 consecutive patients (M/F: 2/10) affected by scleroderma referred…

medicine.medical_specialtyPathologyLungbusiness.industryInterstitial lung diseaseSurfactant protein Dmedicine.diseaseGastroenterologyBlood proteinsSurfactant protein Amedicine.anatomical_structureDLCOInternal medicinemedicineBiomarker (medicine)Respiratory systembusiness1.5 Diffuse Parenchymal Lung Disease
researchProduct

Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD)

2015

Objectives: To determine the prevalence of SAS in patients with ILD and its clinical characteristics, evolution and specific manifestations linked to each antisynthetase antibodies and highlight the need for its screening in ILD. Methods: Retrospective analysis of patients registered in the last two years in our ILD unit, determining antisynthetase antibodies and analyzing clinical, radiological, functional data and illness evolution. Results: 119 ILD patients were included, 10.9% had antisynthetase antibodies, the most prevalent were Jo-1 (46.1%) and PL-12 (38.5%). In PL-12 patients inicial and respiratory syntoms were predominant, whereas in the Jo-1 patients were more frequent extrapulmo…

medicine.medical_specialtyPathologybusiness.industryInterstitial lung diseaseAntisynthetase syndromerespiratory systemmedicine.diseasebehavioral disciplines and activitiesResponse to treatmentrespiratory tract diseasesbody regionsFEV1/FVC ratioInternal medicinemedicineRetrospective analysisIn patientRespiratory systembusinessInterstitial Disease1.5 Diffuse Parenchymal Lung Disease
researchProduct

Chronic obstructive lung disease “expert system”: validation of a predictive tool for assisting diagnosis

2018

Fulvio Braido,1 Pierachille Santus,2 Angelo Guido Corsico,3 Fabiano Di Marco,4 Giovanni Melioli,5 Nicola Scichilone,6 Paolo Solidoro7 1Department of Internal Medicine, IRCCS San Martino di Genova University Hospital, Genoa, Italy; 2Department of Biomedical and Clinical Sciences, University of Milan, Division of Respiratory Diseases, “L. Sacco” University Hospital, ASST Fatebenefratelli-Sacco, Milan, Italy; 3Department of Internal Medicine and Therapeutics, Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, University of Pavia, Italy; 4Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy; 5Center for Precision Medici…

medicine.medical_specialtyValidation studyConcordance analysisbusiness.industryGeneral MedicinePrimary careInternational Journal of Chronic Obstructive Pulmonary Diseasemedicine.diseasecomputer.software_genreObstructive lung diseaseExpert system03 medical and health sciences0302 clinical medicine030228 respiratory systemSample size determinationConcomitantEmergency medicinemedicine030212 general & internal medicineMedical diagnosisbusinesscomputerInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

2019

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and Europea…

medicine.medical_specialtyantisynthetase antibodies; antisynthetase syndrome; arthritis; interstitial lung disease; myositisantisynthetase syndrome; antisynthetase antibodies; arthritis; myositis; interstitial lung diseaseMedizinArthritislcsh:MedicineAntisynthetase syndromeInterstitial lung diseaseAntisynthetase syndromeArticleNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineantisynthetase antibodiesantisynthetase antibodies antisynthetase syndrome arthritis interstitial lung disease myositisddc:610Myositis030203 arthritis & rheumatologyinterstitial lung diseaseAntisynthetase antibodiesbiologyMyositisbusiness.industryArthritislcsh:RInterstitial lung diseaseAutoantibodyGeneral Medicinemedicine.diseasearthriti030228 respiratory systemarthritisTime courseCohortbiology.proteinAntibodyantisynthetase syndromebusinessantisynthetase antibodiemyositis
researchProduct

THU0366 SYSTEMATIC CORONARY RISK EVALUATION (SCORE) MISCLASSIFIES CARDIOVASCULAR RISK IN ANTISYNTHETASE SYNDROME: RESULTS OF THE PILOT MULTICENTRIC S…

2020

Background:Antisynthetase Syndrom (ASyS) is an autoimmune overlap disease characterized by antiaminoacyl-tRNA-synthetase (anti-ARS) antibodies and the classic triad of arthritis, myositis and interstitial lung disease (ILD) (1). Markers of cardiovascular (CV) or cerebrovascular (CVB) risk have never been examined in ASyS.Objectives:Aim of this study (RIsk of CARdiovascular Disease in ASyS: RI.CAR.D.A.) was to test the ability of an established traditional CV risk prediction score (Systematic Coronary Risk Evaluation-SCORE) and its EULAR modified version (mSCORE) to identify ASyS patients at high CV risk. Moreover, we sought to examine for the first time associations of CV surrogate markers …

medicine.medical_specialtybusiness.industryImmunologyInterstitial lung diseaseArthritisAntisynthetase syndromeGold standard (test)Arteriosclerosismedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRheumatologyRheumatologyInternal medicinemedicineCardiologyImmunology and AllergybusinessMyositisSubclinical infectionAnnals of the Rheumatic Diseases
researchProduct

Platelet Activity in Relation to Smoke and Exercise in Patients with Chronic Obstructive Lung Disease: Effects of Platelet Antiaggregating Drugs

1984

Lung tissue is involved in the synthesis and/or metabolism of many vasoactive substances such as histamine, serotonin, dopamine, norepinephrine, bradikinin, angiotensin II and prostaglandins (1).

medicine.medical_specialtybusiness.industryPharmacologymedicine.diseaseAngiotensin IIObstructive lung diseaseNorepinephrine (medication)chemistry.chemical_compoundchemistryDopamineInternal medicinemedicineCardiologyPlateletSerotoninPlatelet activationbusinessHistaminemedicine.drug
researchProduct

Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up☆

2021

Abstract Background Long-term effects of Coronavirus Disease of 2019 (COVID-19) are of utmost relevance. We aimed to determine: 1) the functional capacity of COVID-19 survivors by cardiopulmonary exercise testing (CPET); 2) the characteristics associated with cardiopulmonary exercise testing (CPET) performance; 3) the safety and tolerability of CPET. Methods We prospectively enrolled consecutive patients with laboratory-confirmed COVID-19 from Azienda Sanitaria Locale 3, Genoa. Three months after hospital discharge a complete clinical evaluation, trans-thoracic echocardiography, CPET, pulmonary function tests, and dominant leg extension (DLE) maximal strength measurement were performed. Res…

medicine.medical_specialtymedicine.medical_treatmentBacterial ToxinsArticlePulmonary function testingCardiopulmonary exercise testing; Coronavirus; Coronavirus infection; COVID-19; Lung diseases; Severe acute respiratory syndrome; Echocardiography; Exercise Tolerance; Follow-Up Studies; Humans; Oxygen Consumption; SARS-CoV-2; COVID-19; Exercise TestOxygen ConsumptionInternal medicineDiffusing capacityCoronavirus infectionMedicineHumansSurvivorsAdverse effectLung diseasesRehabilitationExercise Tolerancebusiness.industrySARS-CoV-2VO2 maxCOVID-19Cardiopulmonary exercise testingCoronavirusTolerabilitySevere acute respiratory syndromeEchocardiographyCohortExercise TestCardiology and Cardiovascular MedicinebusinessAnaerobic exerciseFollow-Up StudiesInternational Journal of Cardiology
researchProduct